Inzomelid, a selective, orall small molecule inhibitor of the NLRP3 inflammasome, has been tested in a phase I trial of CAPS (Cryopyrin-Associated Periodic Syndrome) https://t.co/8gO63xO9bC
Links:
Inzomelid completes Phase I studies and shows positive results in the treatment…
https://bwnews.pr/3att5Nb
31-03-2020
